aTyr Pharma completes Phase 3 enrollment for efzofitimod; topline data Q3 2025

aTYR PHARMA INC

Enrolled 268 patients in EFZO-FIT study, exceeding target enrollment.
Trial conducted at 85 centers across 9 countries.
Topline data expected in Q3 2025.
Phase 3 study is pivotal, randomized, double-blind, placebo-controlled.

item 8.01

aTYR PHARMA INC filing history →

Source: SEC EDGAR

accession 0000950170-24-085058

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.